Gilead Viread Rep Retraining Program Requested In FDA Warning Letter
Executive Summary
FDA is requesting that Gilead Sciences retrain its Viread sales reps following allegedly misleading claims of safety and efficacy for the anti-HIV agent cited in a July 29 warning letter to the company
You may also be interested in...
Exhibit Hall Promotion Compliance Is Improving, But Not Perfect, FDA Says
Manufacturers are becoming more compliant with FDA regulations regarding exhibit hall promotions, Division of Drug Marketing, Advertising & Communications Director Tom Abrams said
Exhibit Hall Promotion Compliance Is Improving, But Not Perfect, FDA Says
Manufacturers are becoming more compliant with FDA regulations regarding exhibit hall promotions, Division of Drug Marketing, Advertising & Communications Director Tom Abrams said
Booth Promotion Compliance Improving, FDA Says; Gilead Viread Cited At ICAAC
FDA's Division of Drug Marketing, Advertising & Communications believes that compliance with promotional regulations in the exhibit booth setting is improving